SCHEMBL2573014

SCHEMBL2573014

COC(=O)c1cc2nccn2c(O)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 2/20 0.38
KDM4E B2RXH2 6/20 0.36
ALDH1A1 P00352 6/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
GAA P10253 2/20 0.35
MAPT P10636 1/20 0.35
SYK P43405 4/20 0.35
MAPK1 P28482 3/20 0.35
MAP4K4 O95819 3/20 0.35
MAP4K2 Q12851 3/20 0.35
AURKB Q96GD4 3/20 0.35
JAK2 O60674 2/20 0.35
RET P07949 2/20 0.35
KDR P35968 2/20 0.35
RPS6KA3 P51812 2/20 0.35
PKN2 Q16513 2/20 0.35
SLK Q9H2G2 2/20 0.35
AURKA O14965 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2568941 0.84 NQO2 (0.37) LCKKDM4EALDH1A1HSD17B10HPGD
SCHEMBL14694274 0.75 TNK2 (0.38) LCKKDM4EALDH1A1HSD17B10HPGD
Hydrochloric Acid SCHEMBL14954431 0.74 TNK2 (0.37) LCKKDM4EALDH1A1HSD17B10HPGD
SCHEMBL19697437 0.74 KDM4E (0.41) LCKKDM4EALDH1A1HSD17B10HPGD
SCHEMBL26650392 0.73 MAPT (0.43) LCKKDM4EALDH1A1HSD17B10HPGD
SCHEMBL4256454 0.73 ALDH1A1 (0.39) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL30554130 0.72 PIK3C3 (0.37) LCKKDM4EALDH1A1HSD17B10HPGD
SCHEMBL19697817 0.71 KDM4E (0.43) KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2
SCHEMBL29334102 0.70 KDM4E (0.40) LCKKDM4EALDH1A1HSD17B10HPGD
SCHEMBL2571208 0.68 PDE10A (0.32) MAP4K4MAP4K2AURKBKDRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558468-B1 5, 7-SUBSTITUTED-IMIDAZO [1,2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC (US) 2015-04-01 EP disclosed
US-8962596-B2 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases ARRAY BIOPHARMA INC. (US) 2015-02-24 US disclosed
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2013-05-23 US disclosed
EP-2558468-A1 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES Array Biopharma, Inc. (US) 2013-02-20 EP disclosed
WO-2011130146-A1 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES ARRAY BIOPHARMA INC. (US) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131039-A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES JAK1, JAK3, JAK2 LCK 9/4885KDM4E 1383/4885ALDH1A1 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.